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Abstract 
 
Background: Efavirenz is part of the first-line treatment for HIV patients including South 
Africa with approximately 50% experiencing neuropsychiatric side effects. Objective: 
Systematic review of papers reporting neuropsychiatric side effects with efavirenz published 
between January 2001 and December 2014 to provide guidance.  Results: 13 articles were 
reviewed. Patient ages ranged between 37 to 41 years, with a high percentage males. Scales 
used to measure  incidence and severity of side effects were varied; with disease severity or 
stage not reported. Patients with psychoses were excluded. Most commonly reported side 
effects were a reduction in sleep quality, depression, dizziness and anxiety. These were 
generally mild and not warranting discontinuation of efavirenz. Conclusion: Difficult to 
directly compare the studies. Standardised methods need to be introduced and all patient 
groups represented including the elderly, children, patients with active symptomatic illness 
and more women especially among the African population. 
 
Introduction 
 
Efavirenz is part of the first-line treatment for human immune-deficiency virus (HIV) in 
countries such as South Africa1. It is used as part of triple therapy involving three separate 
drugs as well as fixed-dose combinations. However, it has been shown in published studies 
that almost half of the patients initiated on efavirenz will experience some form of 
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neuropsychiatric side-effect2,3. These side effects are said to occur most commonly within the 
first few days of treatment and resolve within the first four to six weeks of treatment4. 
However, it has been found that such symptoms may persist longer than initially thought5-7. 
The symptoms may persist for up to two years after initiation, although they may not be 
severe enough to warrant the discontinuation of efavirenz6. The aim of this review was to 
provide an overview of the neuropsychiatric side effects caused by efavirenz in order to 
determine the severity as well as their use in particular patient populations including, 
psychiatric patients, to provide future guidance. 
 
Methods 
 
We undertook a systematic review of studies concerning HIV-positive patients on efavirenz 
reporting experiencing neuropsychiatric side effects. All primary studies published from 
January 2001 to December 2014 were included.  
 
The inclusion criteria were that patients had to be over the age of 18 years who were HIV 
positive, the study had to follow patients who were using efavirenz either short term or long 
term and could be retrospective, prospective, cross-sectional or comparison studies. The 
primary outcome must indicate the incidence of neuropsychiatric side effects with a 
secondary outcome being the number of discontinuations due to these side effects. The 
electronic databases searched included; Biomed Central, EBSCOhost, Emerald, ISI web of 
knowledge, JSTOR, PubMed Central, SAGE, ScienceDirect and SpringerLink. The search 
terms used were; efavirenz, HIV-positive, neuropsychiatric, side effects, to find primary 
studies. A broad search was done initially using the keywords efavirenz, HIV-positive and 
side effects. The keywords were then refined (efavirenz, HIV, neuropsychiatric side effects) 
to identify more specific studies. Articles that contained these keywords in the title or abstract 
were extracted and their relevance was determined. Review articles as well as those including 
children under the age of 18 years and patients with co-morbidities were excluded. 
 
Those that were considered relevant were read in entirety by the principal researcher (RG) to 
determine potential inclusion. The articles included and excluded are outlined in Figure 1. 
The search was limited to English language full-text articles published in journals accessible 
via the Nelson Mandela Metropolitan University database.  
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Figure 1. Articles included and excluded in the systematic review 
 
  
IDENTIFICATION 
Records identified through database 
searches (n=834) 
Records after duplicates removed 
(n=722) 
Records excluded (n=137) 
Reviews (n=137) SCREENING 
Full text articles assessed for 
eligibility (n=585) 
Full text articles excluded (n=572) 
Included children under the age of 
18 years or patients with co-
morbidities (n=246) 
Not focused on neuropsychiatric 
side effects or severity of efavirenz 
(n=326) 
ELIGIBILITY 
Studies included for analysis (n=13) 
INCLUDED 
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Results 
 
x Overview of studies 
 
Of the studies analysed, two were randomised controlled trials, one was double-blind, but not 
randomised, four were cross-sectional cohort studies, four were prospective cohorts, one a 
retrospective analysis and another a longitudinal study. Four studies randomised patients to 
either efavirenz or another regimen. The other studies included patients who were already 
receiving efavirenz or a different regimen and were compared against each other. Five of the 
studies were conducted in Europe (Spain and France), four in the United States of America 
(USA) and one each in Australia, South Africa and the United Kingdom. Details of the 
studies are summarised in Table 1.  
 
Insert Table 1 
 
x Patient populations 
 
Patients were recruited mostly from outpatient clinics (five studies). Two of the studies were 
a subset of a larger clinical trial. One study made use of a workplace HIV-programme to 
UHFUXLWSDWLHQWVDQGDQRWKHUUHFUXLWHGSDWLHQWVIURPWKHLQYHVWLJDWRUV¶SULYate practices. The 
studies all showed the patient population being at least 70% male with some studies showing 
as high as 90% male dominance. The average age of the patients across all of the studies was 
37 years to 41 years old.  
 
The inclusion criteria varied widely between studies. All participants had to be aged 18 years 
or older, however, the duration of efavirenz therapy varied from initiation up to at least one 
year of therapy. Fumaz and colleagues6 were considering the long-term side effects 
experienced with efavirenz and stated that the patient had to be on an efavirenz-containing 
regimen for at least one year in order to be included. Clifford and colleagues3 followed 
consenting patients for 184 weeks after being randomised to efavirenz. Other studies were 
considering the immediate effects and focused on patients who had just been initiated on 
efavirenz or were using efavirenz for three to six months.  
 
The standard dose of efavirenz is 600mg daily generally taken at bedtime9. Only four studies 
explicitly stated the dose of efavirenz being received by the patients. One study made use of 
three 200mg tablets that had to be taken together at bedtime while others made use of single 
600mg tablets and one study4 randomised patients to stepped dose of efavirenz or efavirenz 
600mg daily. Although the standard dose of efavirenz is 600mg daily, it is dosed based on the 
weight of the patient. Patients weighing less than 40kg receive 400mg of efavirenz at bedtime 
as opposed to 600mg, which may impact on the incidence and/or the severity of side effects 
experienced.  
 
x Measuring protocols 
 
In terms of the instruments used to measure the neuropsychiatric side effects caused by 
efavirenz, there was some diversity. The instruments used are summarised in Table 2. The 
only common scales were the Symptom Checklist-90-Revised (SCL-90-R) and the Medical 
Outcome Study for HIV-positive patients (MOS-HIV) scale which were used by two studies. 
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Seven of the studies used clinicians to interview participants concerning side effects, whereas 
four studies allowed patients to answer questionnaires themselves. The exception was the 
study conducted by Fumaz and colleagues6 who used a combination of both. Further details 
are provided in Table 2. 
 
Insert Table 2 
 
x Side-effects  
 
The most commonly reported side-effects included sleep quality (nine studies), depression 
(eight studies), dizziness (seven studies) and anxiety (seven studies). Some other notable 
problems reported included impaired concentration (five studies), abnormal dreams (four 
studies) and light-headedness (four studies). More serious side-effects such as suicidal 
ideation and paranoia were each reported just once. Studies tend to demonstrate that the 
symptoms are prominent in the first few weeks of therapy and then decline in severity, with 
the exception of the study by Fumaz and colleagues6 who showed that symptoms may persist 
for up to a mean of two years. Several studies7,9,11,12 also suggested that side-effects can 
persist for up to one year after the initiation of efavirenz and recommend that patient 
monitoring continue past the first few weeks of therapy. Hawkins and colleagues7 showed 
that the side effects of efavirenz can persist up to a year after the initiation of treatment. 
However, the side effects present after one year of therapy are not severe and are tolerated by 
patients. Gutierrez and colleagues12 showed that patients who discontinued efavirenz were 
using the mediation for a range of 16 months to 34 months. Detailed information is provided 
in Table 3. The package insert of efavirenz does mention that the drug can cause 
neuropsychiatric side effects; however, the incidence is stated as rare and includes only 
anxiety, apathy, emotional lability, euphoria, hallucinations and depression8.  
 
Insert Table 3 
 
x Severity of side-effects 
 
The severity of the side-effects was recorded by five studies. Different scales were used to 
evaluate severity. Gutierrez and colleagues12 utilised the World Health Organisation (WHO) 
severity scale, Hoffman and colleagues13 allowed providers to grade the severity of clinical 
side effects, Nelson and colleagues14 made use of the Division of AIDS Grading Table, and 
Rihs and colleagues10 used the Depression Anxiety and Stress Scale (DASS) to measure the 
severity of anxiety, depression and stress. Gutierrez-Valencia and colleagues4 did not state 
which scale was used to evaluate the severity of the side-effects.  
 
Almost all of the studies reported patients discontinuing efavirenz treatment due to intolerable NPSEs; 
however, this occurred in the minority of patients. Generally though patients experienced mild 
symptoms as expressed by the various scales. However, it is worthy to note that some 
patients may experience intolerable side effects and require the discontinuation of efavirenz. 
Nelson and colleagues14 divided side effects caused by efavirenz into neurological and 
psychiatric. A total of 33.4% of patients on efavirenz were reported to have demonstrated at 
least one grade one to four neurologic side effect and 39% of patients using efavirenz 
reported at least one grade one to four psychiatric side effect. In both cases, these values were 
higher when compared to the group of patients receiving etravirine (20.2% neurologic side 
effect and 11% psychiatric side effects). Rihs and colleagues10 demonstrated that patients 
prescribed efavirenz had experienced severe to extremely severe anxiety, depression and 
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stress, although they were all small groups of patients. Gutierrez-Valencia and colleagues3 
separated patients into a stepped dose and a full dose efavirenz group and explored a variety 
of side effects. They reported a higher number of patients (n = 6) from the full dose group 
experiencing severe side-effects at day 30 of the follow-up compared to the stepped dose 
group (n = 2).  
 
The studies all showed that these side effects were transient in nature and not severe enough 
to warrant the discontinuation of efavirenz in the majority of patients. However, if the side-
effects persist, as shown by Fumaz6, Hawkins7, Rihs10 and Leutscher11, patient adherence to 
efavirenz may decline even if the side effects are mild or moderate in severity.  
 
Discussion 
 
Due to the varied nature of the measuring instruments used, it is difficult to directly compare 
these trials in a systematic review. However, in spite of the varying nature of these studies, 
there are some common findings. All published studies included in the review showed that 
the side effects caused by efavirenz can be tolerated by most patients and that these side 
effects tend to be transient in nature. There has not been any significant evidence of efavirenz 
causing suicidal ideation or paranoia in patients. In fact, a study by Napoli18 and colleagues 
employed a technique to identify associations between drugs and adverse reactions. The 
results showed that efavirenz was not associated with an increased risk of suicidality. 
Similarly, a study conducted by Smith and colleagues19 showed that there was no higher rate of 
completed suicide in patients using efavirenz. However, Mollan and colleagues20 found that there is an 
increased risk of idealised, attempted, or completed suicide with efavirenz. Only one of the studies 
focused on in this review mentions suicide. This means that this particular side effect was not detected 
or not significant amongst the participants of the other studies. The neuropsychiatric symptoms 
have, however, been shown to persist for several years after the initiation of therapy and 
appropriate caution should therefore be taken. Continuing patient monitoring and counselling 
needs to be conducted in order to identify late-emergent side-effects.   
  
Patients with a history of psychoses, active psychoses or depression were included in only 
one study21. Blanch and colleagues21 referred participating patients to be interviewed by a 
psychiatrist. It was found that only 54.8% of their patients had a psychiatric disorder, but 
83.9% reported at least one psychiatric symptom at baseline, 71% reported some form of 
psychiatric symptom after the initiation of efavirenz and 13% dropped out of the study due to 
psychiatric side effects. The package insert of efavirenz does not state that efavirenz is 
contraindicated in patients with a psychiatric disorder8. As mentioned, the South African 
National consolidated Guidelines1 state that an alternative may be used in place of efavirenz 
where the patient has significant psychiatric co-morbidity. However, the CD4 count has an 
impact on the alternative chosen. If a female patient has a CD4 count of less than 250 and a 
male patient has a CD4 count of less than 400, nevirapine may be used as an alternative. If 
the CD4 count of the female patient is equal to or more than 250 and the male patient has a 
CD4 count of 400 or more, the lopinavir/ritonavir combination should be used instead. It 
must be remembered that nevirapine has the potential to cause significant hepatotoxicity as 
well as skin abnormalities20. However, there are significant drug interactions between 
ritonavir and psychotropic drugs such as clozapine, carbamazepine and sedatives and 
hypnotics such as diazepam, midazolam and zolpidem21. Also of note, a retrospective 
analysis that compared a large group of patients receiving efavirenz to a large group of 
patients receiving nevirapine showed that there were no significant differences between them 
in terms of treatment withdrawal. This further supports the idea that the neuropsychiatric side 
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effects caused by efavirenz are not severe enough to warrant its discontinuation in the 
majority of patients24.   
 
Even though efavirenz is no longer used as part of the first line treatment in the United States 
of America25 or the United Kingdom26, it still forms part of the treatment backbone in South 
Africa which has the largest HIV epidemic in the world27. Several other countries in Africa 
with an HIV prevalence of more than 10% use efavirenz as part of the recommended first line 
treatment of naïve patients27. Agents used as first line treatment in the United States of 
America and the United Kingdom are reserved for second or third line use in the African 
countries mentioned below. This demonstrates the importance of a thorough understanding of 
efavirenz as is it still widely used in developing countries. The various regimens are 
summarised in Table 4. 
 
Table 4. First line ART regimens for treatment-naïve patients of various countries 
 
Country Date of Guidelines Recommended first line treatment 
for treatment-naïve patients 
Botswana28 2012 tenofovir +lamivudine + efavirenz 
(preferably as a single dose 
combination) 
Lesotho29 2014 tenofovir + lamivudine + efavirenz 
(preferably as a single dose 
combination) 
Malawi30 2014 tenofovir + lamivudine + efavirenz 
Namibia31 2010 tenofovir + lamivudine + nevirapine 
(if the CD4 count in women is 
>350cells/µl, or if the CD4 count in 
men is >400 cells/µl and the man is 
classified as WHO stage 3 or 4, 
efavirenz should be used instead of 
nevirapine) 
South Africa1 2014 tenofovir + lamivudine + efavirenz 
(preferably as a single dose 
combination) 
Swaziland33 2015 tenofovir + lamivudine + efavirenz 
United States of America24 2015 abacavir +lamivudine + dolutegravir 
OR 
tenofovir + emtricitabine + 
dolutegravir 
OR 
tenofovir + emtricitabine + 
elvitegravir/cobicistat 
OR 
tenofovir + emtricitabine + raltegravir 
(a suitable regimen is to be chosen 
based on laboratory investigation 
results as stated in the full Guideline) 
United Kingdom25 2015 tenofovir + emtricitabine + 
atazanivir/ritonavir 
OR 
darunavir/ritonavir 
OR 
dolutegravir 
OR 
elvitegravir/cobicistat 
OR 
raltegravir 
OR 
rilpivirine as preferred agents 
OR 
efavirenz as an alternative agent 
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Alternative regimen 
abacavir + lamivudine + any of the 
above 
Zimbabwe34 2013 tenofovir + lamivudine + efavirenz 
(preferably as a single dose 
combination) 
 
The Malawian30, South African1 and United Kingdom Guidelines26 state that if a patient has a 
history of, or current, mental illness that patient should not be given efavirenz. The 
Guidelines published in the United States of America25 acknowledge that efavirenz causes a 
myriad of neuropsychiatric side-effects (NPSEs), some of which may be severe, but do not 
state that efavirenz should not be given to such patients or that therapy should be switched to 
an alternative agent. The HIV Treatment Guidelines of Swaziland32 suggest that patients with 
mental illness, even such severe conditions such as schizophrenia or schizoaffective disorder, 
should not be discriminated against in terms of antiretroviral treatment (ART). These patients 
should be assessed individually and appropriate decisions made using the screening tools 
provided in the Guideline. The Guidelines of Swaziland32 also warn that efavirenz is 
associated with mental health disturbances such as bad dreams and being in an altered state of 
mind, thus patients should be encouraged to take efavirenz before bedtime. 
 
There have been suggestions that the plasma level of efavirenz may be a risk factor for the 
development of neuropsychiatric side effects; however, there has not been a consensus 
concerning the threshold concentration12,34. Given that studies have shown that genetic 
variations, particularly of the enzyme CYP2B6, in patients affect the plasma levels of 
efavirenz9,35, studies need to be conducted in a broader range of countries to determine 
region-specific guidelines for efavirenz dosing. These polymorphisms have been shown to be 
more common in patients of African descent and such patients should be monitored more 
closely as they are more likely to experience higher plasma levels of efavirenz and be 
susceptible to neuropsychiatric side effects35. This is particularly important as only one of the 
studies included patients from South Africa13. This indicates that there is a need for further 
safety and pharmacovigilance studies in Africa to determine the clinical importance of this 
variation. This is endorsed by recent reports which showed that a nevirapine safety signal was 
detected in Namibia using their adverse reporting database - VigiFlow®- after shifting the 
initiation of nevirapine to patients with higher CD4 counts than previously recommended. 
This resulted in the Ministry of Health in Namibia halting this move and returning to the 
previous recommendations36. This is important as the majority of people with HIV live in 
low- and middle-income countries, particularly sub-Saharan Africa, and HIV 
disproportionately affects young women in these countries37,38. This compares with the high 
proportion of men in the published studies from Europe and the USA.   
 
All of the studies included in this review had a majority male population and there was an 
average age range of 37 to 41 years. This implies a knowledge gap in special populations 
such as older patients, paediatrics and patients with a psychiatric illness as these factors will 
impact the treatment chosen. Such patients need to be included in studies in addition to 
including more women and patients in Africa in order to obtain a complete picture and 
representative sample.  Consequently, it is difficult to provide additional guidance on the use 
of EFV especially in patients in Africa apart from that already documented.  
 
None of the studies indicated the WHO stage of HIV. However, this has not been considered 
as a possible risk factor in the development of neuropsychiatric side effects of efavirenz. 
Determining risk factors for side-effects may assist with discerning possible causes of the 
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problem. The location and sample population has also shown to be of importance in studies 
concerning efavirenz and has to be taken into account when generalising results.  
 
Limitations 
 
There were only small numbers of female patients in the studies compared to males, with 
only limited follow-up. In addition, since only one of the studies was conducted in an Africa 
setting, the results may not be generalisable to all countries and settings due to the varied 
nature of efavirenz metabolism in patients of African descent. We are also aware that the 
methodologies of the included studies are varied and do not allow for direct comparisons and 
that the small number of studies sourced due to our strict methodology, which limited included 
studies to English language full-text articles published in journals accessible via the Nelson Mandela 
Metropolitan University database, does serve as a limitation to this study. However, we do not 
believe that the inclusion of more studies would have significantly altered the conclusions of 
our findings.  
 
Conclusion 
 
Standardised methods for measuring outcomes need to be determined. Similar studies need to 
be conducted in more countries to represent the various populations and their differences 
across continents. In the studies included in this systematic review, the neuropsychiatric side 
effects of efavirenz do not appear severe enough to warrant discontinuation of the 
medication, even if they may persist longer or emerge later than initially thought.  Continuous 
pharmacovigilance, adherence counselling and support is important to these, and other 
patients, as efavirenz will form part of a lifelong regimen.  
 
Key messages 
 
x The neuropsychiatric side effects caused by efavirenz may persist longer than the first  
four to six weeks of treatment as initially thought 
 
x These side effects are not generally severe enough to warrant the discontinuation of 
efavirenz 
 
x Older patients, paediatric patients and patients with active symptomatic mental illness 
need to be included in studies to obtain a representative sample. Similarly for Africa there 
needs to be more women included in studies monitoring the side-effects of treatments for 
HIV 
 
x Patients need to be provided with continuous adherence education to enhance the 
effectiveness of treatment 
 
Expert commentary 
 
HIV is a multifaceted condition, particularly among African regions where often patients 
need to make the choice between food and medication. Providing patients with medication 
that is effective, would cause limited side-effects and is simple to take is the aim of any 
healthcare programme. The introduction of the fixed dose combination has improved 
adherence to ART. The systematic review confirmed that efavirenz (EFV) does cause 
neuropsychiatric side effects in an appreciable number of patients, which include changes in 
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sleep quality, dizziness, anxiety and depression; however, the side-effects seen are generally 
mild and do not typically warrant discontinuation. They can though be severe in some 
patients, leading to discontinuation and switching to other treatments. Having said this, 
currently efavirenz forms a major part of HIV treatment in sub-Saharan Africa, which is 
likely to remain. Its utilisation would even appreciably increase in South Africa iIWKHµtest 
DQGWUHDW¶option, i.e. if a patient tests HIV-positive, ART is started regardless of the CD4 
count, was introduced, which South Africa is currently considering as a future treatment 
strategy. The situation in Southern Africa enhances the argument that efavirenz is still a 
medicine that requires more understanding among different African settings, given the likely 
increases in its utilisation as well as concerns with the make-up and the different genetic 
variations between HIV populations in Africa versus Western countries. In the meantime, 
patients will need to be appropriately screened before initiating efavirenz. They will also need 
to be continuously monitored for side effects and current adherence given the prevalence of 
side-effects with EFV.  
 
Five-year view 
 
Africa has the highest burden of HIV in the world. Given the various social aspects 
contributing to the spread of the disease, it is unlikely that this situation will change 
significantly over the next five years. The cost of medication will become even more of a 
determining factor in treatment decision-making. Adherence to treatment currently is, and 
will always be, a concern in patients expected to take lifelong treatment. Advances in 
medicine may result in a vaccine against HIV being developed and rolled out over the next 
five years. There may also be improvements in technology, leading to resistance testing in all 
patients testing HIV-positive before being initiated on treatment. However, for these 
advances to be implemented in countries with high HIV burden and limited resources, cost 
will be continue to a major factor leading to continued use of treatments such as EFV. It is 
hoped that more studies are conducted among HIV patients in Africa given the different 
patient patterns to Western countries and different genetic variations. This will help to further 
guide treatment choices.  
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Table 1. Demographics of studies 
Authors, 
publication year 
and country 
Type of study Setting Follow-up period Number of 
patients/controls 
Average age of patients % Male patients Duration of 
efavirenz 
treatment 
Blanch J et al. 
200121 
(Spain) 
Open-label, prospective, 
observational study 
HIV hospital 
outpatients 
12 weeks 31/- 41 years±10 years 71% 12 weeks 
Clifford DB et al. 
20055 
(USA) 
Substudy of randomised, 
double-blind, controlled trial 
(A5095) 
Multicentre 
academic clinical 
trial units 
24 weeks 283/- Median age ± 37 years 
(efavirenz group), 38 
years (non-efavirenz 
group) 
82% (efavirenz 
group), 80% (non-
efavirenz group) 
184 weeks 
Clifford DB et al. 
200915 
(USA) 
Substudy of A5095. 
Prospective, comparative, 
placebo-controlled study 
Substudy 184 weeks Efavirenz only ± 86, Various 
regimens ± 37, Late long-
term efavirenz ± 21, Non-
efavirenz only - 33, Total - 
177 
Efavirenz only ± 39.2 
years, Various regimens ± 
37.4 years, Late long-term 
efavirenz ± 40 years, 
Non-efavirenz only ± 40.5 
years 
Efavirenz-only  - 
85%, Various 
regimens ± 70%, 
Late long-term 
efavirenz ± 81%, 
Non-efavirenz only 
± 81% 
24 weeks 
Fumaz CR et al. 
20056 
(Spain) 
Cross-sectional comparative 
study  
Hospital Cross-sectional study Efavirenz ± 60, Protease 
inhibitor ± 60 
Efavirenz - 41.4 
years±8.05 years,         
protease inhibitor- 39.2 
years±7.7 years 
Efavirenz - 75%, PI 
± 70% 
Average time 
91.1±39.5 weeks for 
efavirenz patients 
and 119.9±67.4 
weeks for the PI 
patients 
Gutierrez F et al. 
200512 
(Spain) 
Longitudinal study  Hospital 18 months 17/- Median age - 40 years 82.4% Median time was 18 
months (range six 
months to 27 
months) 
Gutierrez-
Valencia A et al. 
20094 
(Spain) 
Randomised, double-blind, 
controlled trial 
,QYHVWLJDWRUV¶
clinical practice 
24 weeks 108 patients  
(Full dose group ± 50, 
Stepped dose group - 58) 
39 years Full dose group ± 
80%, Stepped dose 
group ± 77.6% 
24 weeks 
Hawkins T et al. 
20057 
(USA) 
Cross-sectional 
questionnaire-based cohort 
Not indicated Cross-sectional 77 protease inhibitor group 
and 75 efavirenz group 
43 years ±7.4 PI group 
and 40 years ± 8.1 years 
efavirenz group 
95% protease 
inhibitor group and 
92% efavirenz 
group 
345±250 days for 
patients on efavirenz 
and 582±445 days 
for patients on PIs 
Hoffman CJ et al. 
200813 
(South Africa) 
Prospective cohort Workplace Included patients 
started on highly active 
antiretroviral therapy 
(HAART) over 3 years 
(2002-2005) and 
followed up until 
November 2006 
853/- Median age - 40 years 98% 378 days 
Leutscher PDC et 
al. 201311 
(Denmark) 
Prospective cohort University hospital 
outpatient HIV 
clinic 
Patients initiated on 
therapy from January 
2000 until December 
2009 were included 
and followed up until 
December 2010 
276 (168 on efavirenz)/- Median age - 39 years Efavirenz group ± 
71%, non-efavirenz 
group - 53% 
Patients were on 
efavirenz between 
one and 11 years 
Lochet P et al. 
200316 
(France) 
Cross-sectional study HIV outpatients at 
hospitals 
Cross sectional 174/- Median age - 40 years 78.2% Median duration ± 
14.5months (range 3 
to 43.5 months) 
Nelson M et al. 
201114 
(UK) 
Double-blind placebo 
controlled trial 
Clinical trial 48 weeks (primary 
assessment of 
neuropsychiatric 
symptoms at 12 weeks) 
157/- 38 years 81%  
Rihs TA et al.10 Single-centre, cross-sectional 
case controlled  
Outpatient HIV 
clinic 
Cross sectional 32/32 Efavirenz group -  43 
years±10 years Control - 
Efavirenz -97% 
Control - 97% 
Average duration - 
14±5 months in the 
(Australia) 44 years±10 years  efavirenz group and 
24±14 months in the 
control group 
Ward DJ and 
Curtin JM. 200617 
(USA) 
Retrospective analysis HIV-specialty 
private practice 
3 years 40/- Median age 41 years 97.5% Average of 27 
months on efavirenz 
(range 3-69 months) 
 
 
 
 
 
  
Table 2. Statistical methods and outcomes 
Primary author Evaluation methods Statistical methods Primary outcome Secondary outcome 
Blanch J21 - 100-point Karnofsky Scale (clinician 
administered)  
- Psychological and physical 10-point self-
report scale (self-administered)  
- Structured Clinical Interview of the 
clinical version of the Diagnostic and 
Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) (psychiatrist 
administered) 
- Validated Spanish adaptations of the 
Symptom Check List-90-Revised (SCL-90-
R) 
- Medical Outcome Study for HIV-positive 
patients (MOS-HIV) 
- Univariate repeated-measures 
ANOVA followed up with 
univariate simple contrast effects 
test  
- Friedman test  
- Wilcoxon signed-rank tests -
Bonferroni adjustment 
- Univariate and multivariate 
regression analyses  
 
- Four patients discontinued 
efavirenz due to 
neuropsychiatric side effects 
- Patients who completed the 
follow-up demonstrated a 
decrease in SCL-90-R total 
score and in several subscales 
interpersonal sensitivity, 
depression and anxiety 
- No changes in MOS-HIV   
- Having fewer years of 
education  
-Having fewer baseline central 
nervous system symptoms 
- Reporting better baseline 
physical status  
- Having higher baseline scores 
in the Health Transition 
subscale of the MOS-HIV and 
in the Somatisation subscale of 
the SCL-90-R (associated with 
more neuropsychiatric side 
effects) 
Clifford DB5 - Trail Making Tests (series A and B) and 
the Digital Symbol Substitution Test 
- Nonparametric tests 
- Generalised estimation equation 
modelling 
- Wei-Johnson test  
- Spearman correlation efficient 
- All components improved  
- Higher levels of efavirenz were 
associated with slightly lower 
responses 
- Efavirenz-related central 
nervous system scores increased 
- Median change of bad dream 
scores and anxiety increased 
while global depression score 
decreased 
- Neurocognitive performance 
was maintained without 
decline over the three years of 
the study 
- This provides some 
reassurance that chronic 
neurotoxicity is unlikely in 
many patients 
Clifford DB15 - Trail Making Tests (series A and B) - Wilcoxon signed rank tests  - Efavirenz -related symptoms 
was higher than baseline at final 
None recorded 
- Digit Symbol Test 
- Pittsburgh Sleep Quality Index 
- State-Trait Anxiety Inventory for Adults 
- Center for Epidemiologic Studies 
Depression scale  
- Specially designed questionnaire 
- Wilcoxon rank sum tests  assessment.  
-µ%DGGUHDPV¶GHWHFWHGDPHDQ
increase  
- Anxiety increased  
- When efavirenz-only patients 
are compared with those never 
receiving efavirenz, there is no 
statistically significant 
difference in changes over the 
study 
Fumaz CR6 - MOS-HIV questionnaire  
- Profile of Mood State 
- Kolmogorov-Smirnov test  
- Mann-Whitney nonparametric 
test  
- X2 test 
- Fisher exact test 
- Spearman nonparametric test 
- 54% of efavirenz patients 
reported at least one 
neuropsychiatric disorder within 
the four weeks before the visit  
- Dizziness (21.7%), sadness 
(36.78%), mood changes 
(26.7%), irritability (30%), light-
headedness (28.3%), 
nervousness (30%), impaired 
concentration (26.7%), abnormal 
dreams (48.3%), somnolence 
(15%) 
- Mean efavirenz levels 
showed no significant 
differences between those with 
and without neuropsychiatric 
disorders 
- 60% of efavirenz patients 
reported adherence and 55% of 
protease inhibitor patients 
Gutierrez F12 - Semi-structured interview (included 
questions exploring common presumptive 
efavirenz -related side effects)  
- WHO toxicity scale 
- Simplified Medication Adherence 
questionnaire 
- Student t test 
- Receiver operating 
characteristic values  
- Contingency tables 
- Multivariate analysis 
- Logistic regression 
- Four patients discontinued due 
to side effects 
- Adherence to efavirenz therapy 
was >90% for 16 of 17 patients  
- Ten patients reported 
neuropsychiatric side effects 
during the observation period, 
mostly sleep disturbances  
- Patients having plasma levels 
of more than 2.74µg/ml  were 
5.68 times more likely to 
experience central nervous 
system toxicity 
- Others include dizziness (6), 
insomnia or abnormal dreaming 
(5), impaired concentration and 
attention span (2), depression 
(2), obsessive disorder (1), 
drowsiness (1), irritability (1) 
and light-headedness (1) 
- Efavirenz plasma levels were 
higher for patients with 
neuropsychiatric side effects  
Gutierrez-Valencia A4 - 11 questions on common efavirenz -
related neuropsychiatric side effects 
(dizziness, feelings of drunkeness, 
headache, impaired concentration, mood 
disorders, anxiety and depression) 
- Validated 13-item protocol that measured 
subjective sleep quality, somnolence, 
insomnia and nightmares 
- X2 test  
- Student t test 
- Mann-Whitney-Wilcoxon test 
- During the first week, 55.5% 
developed efavirenz-related 
neuropsychiatric side effects 
(these were more frequent in the 
full dose group (66%) than the 
stepped dose group (46.5%)  
- Incidences of dizziness (66% 
vs 32.8%), feeling of hangover 
(45.8% vs 20.7%), impaired 
concentration (22.9% vs 8.9% ) 
and hallucinations (6.1% vs 0%) 
were higher and more severe in 
the full dose compared to 
stepped dose group 
- None recorded 
Hawkins T7 - SCL-90-R - Univariate analysis 
- Student t test 
- X2 test 
- Multivariate analyses 
- In the first six months, worse 
scores were seen in 39 of the 75 
patients receiving efavirenz  
- The efavirenz group had higher 
scores for somatisation, anxiety, 
obsessive-compulsive disorder, 
the Global Severity Index and 
the Positive Symptom Distress 
Index with trends for higher 
- Efavirenz -related 
neuropsychiatric symptoms 
can last up to 200 days after 
the initiation of treatment  
- Severity of the side effects 
declined over time in efavirenz 
-treated patients compared to 
patients treated with a protease 
scores in paranoid ideation and 
depression 
-After 12 months, the efavirenz 
group scored lower scores than 
the protease inhibitor treated 
group for somatisation, 
Interpersonal Sensitivity, Global 
Severity Index and Positive 
Symptom Total 
inhibitor-based regimen 
Hoffman CJ13 - Structured visit forms and results from 
routine and acute laboratory testing  
- Special side event reporting form 
- Pre-HAART person-years at 
risk were calculated from the first 
clinical evaluation or one year 
before the initiation of HAART 
- Person-years at risk on HAART 
were calculated from the time of 
HAART initiation to the earliest 
of the following: time of event, 
change or discontinuation of 
HAART, date of last clinical or 
laboratory encounter in the 
database or one year of follow-up 
on HAART 
- CNS effects with efavirenz ±
187 patients  
- 37/100person years, 95% 
confidence interval 32-43 
- Subjects on co-trimoxazole 
had a higher rate of central 
nervous system symptoms 
Leutscher PDC11 - Review of medical records - X2 test - 54% (n=90) of patients in the 
efavirenz group (n=168) 
discontinued efavirenz 
- Overall, 51% of patients 
discontinued efavirenz 
throughout the study 
- A small percentage of the 90 
patients (n=17%) discontinued 
efavirenz during the first month 
of therapy, 32% discontinued 
- Other reasons for 
discontinuation of efavirenz 
were pregnancy, treatment 
failure or non-compliance 
- Once efavirenz was 
discontinued, there was 
resolution of the 
neuropsychiatric side effects in 
61% of patients in the first-line 
efavirenz group 
between one and 12 months and 
the remaining 51% discontinued 
after more than one year 
- Neuropsychiatric disturbances 
was the most common reason 
for discontinuation among both 
patients  discontinuing the initial 
efavirenz-based regimen as well 
as those discontinuing efavirenz 
as part of a second-line regimen 
- Among the first line treatment 
patients, 50% were discontinued 
after one year of therapy 
- No differences in gender 
distribution, country of origin, 
history of HIV transmission or 
viral load or CD4 counts 
Lochet P16 - SENSIO questionnaire  - None indicated - Neuropsychiatric side effects 
occurred mainly in the first 
month of treatment  
- Sleep disturbances and 
dizziness occurred mostly at the 
beginning of efavirenz treatment 
- Neuropsychiatric side effects 
which persisted or worsened 
include anxiety, behavioural 
troubles, sadness and cognitive 
disorders 
- Late neuropsychiatric side 
effects included abnormal 
dreams, nocturnal waking, 
memory disorders, concentration 
difficulty, morning tiredness and 
daytime drowsiness 
- None recorded 
Nelson M14 - Division of AIDS grading table - Logistic regression - 13 of the 79 patients in the - Change in HIV-RNA to week 
 etravirine arm and 36 of the 78 
patients in the efavirenz arm 
showed at least one grade one to 
four drug-related treatment-
emergent neuropsychiatric side 
effect 
- Four of 79 patients in the 
etravirine arm and 13 of 78 in 
the efavirenz arm showed at 
least one grade two to four drug-
related treatment0emergent 
neuropsychiatric side effect  
12 was -2.9log10 in both 
treatment arms 
- Median rise in CD4 cell 
counts was 146cells/µl in the 
etravirine arm and 121 cells/µl 
in the efavirenz arm  
Rihs TA10 - Depression Anxiety and Stress Scale  
- Cognitive Failures Questionnaire 
 
- Paired t-tests  
- :LOFR[RQ¶VVLJQHGUDQNWHVW  
- X2 tests 
- )LVKHU¶VH[DFWWHVWV 
- Higher stress scores in the 
efavirenz group 
- 19% reported severe to 
extremely severe levels of stress 
- 19% of patients treated with 
efavirenz reported severe to 
extremely severe levels of 
anxiety 
- This group reported unusual 
dreams 
- No significant differences 
were found between the groups 
concerning cognitive 
impairment, fatigue, dizziness, 
derealisation or 
depersonalisation 
Ward DJ19 - No formal measuring tool used - Paired Student t test - 14 patients reported full 
recovery after switching 
- The other six patients reported 
significant improvement in 
symptoms 
- Three of the six patients had a 
history of depression before 
starting efavirenz 
- None recorded 
 Table 3. Side effects recorded 
Primary Author Side effects and consequences 
Blanch J21 Depression, anxiety, dizziness, light-headedness, feeling disengaged from reality. There were nine patients who dropped out of the study, four of whom did so due 
to intolerable NPSEs. Efavirenz was effective in decreasing viral load and improved the psychological distress level. Patients who maintained efavirenz treatment 
showed a decrease in interpersonal sensitivity during the first four weeks and a decrease in depression up to the first three months. The study found no association 
between NPSEs and personal psychiatric history. 
Clifford DB5 The significant increase in the NPSEs seen during the first week of treatment declined towards baseline levels during the study, but remained higher than baseline 
levels at the final visit. These side effects were not significantly associated with efavirenz trough levels measured at the final visit. Changes in the global sleep 
VFRUHRYHUWKHVWXG\ZHUHQRWVLJQLILFDQWDOWKRXJKWKHµEDGGUHDPV¶TXHVWLRQGHWHFWHGDPHDQLQFUHDVHDIWHUZHHNV7KHUHwas a statistically significant 
decrease in depression symptoms over the course of the study. The symptoms of anxiety increased by a median of four points as measured by the State Anxiety 
Index. There were 31 patients who discontinued treatment, 11 did so due to NPSEs. 
Clifford DB15 Sleep quality scores changed little over time. Patients who were not receiving efavirenz had significantly poorer sleep quality at week four as compared to the 
efavirenz group. All participants experienced anxiety throughout the study. Changes in depressed mood were similar in both groups.  
Fumaz CR6 Patients on efavirenz reported higher prevalence of dizziness, sadness, mood changes, irritability, light-headedness, nervousness, impaired concentration, 
abnormal dreams and somnolence. Other side effects included fatigue, headaches, euphoria, difficulty sleeping. There was no correlation between the plasma 
levels of efavirenz and the presence of NPSEs. There were no significant differences in quality of life between patients on efavirenz and those not.  
Gutierrez F12 Overall, 10 patients of the 17 experienced NPSEs, mostly sleep disturbances. CNS effects included dizziness, insomnia or abnormal dreams, impaired 
concentration and attention span, depression, drowsiness, irritability and light-headedness. In six of the 10 patients, NPSEs were mild. In the other four cases, 
CNS toxicity was moderate or severe leading to the discontinuation of efavirenz. This occurred at months six, eight, 11 and 13 of the study. Plasma levels of 
efavirenz were found to be higher in patients experiencing NPSEs.  
Gutierrez-Valencia A4 There were 12 patients who discontinued the study due to adverse effects. Five of these patients were in the stepped-dose group and seven in the full-dose group. 
Dizziness, feelings of drunkeness, impaired concentration and hallucinations, sleep disorders and nightmares were the most commonly recorded side effects. 
Other side effects included headache, mood disorders, disorientation, anxiety, depression. Throughout the second week of the study the incidence of NPSEs was 
similar in both groups, although the more severe NPSEs occurred in the full-dose group.  
Hawkins T7 Somatisation, obsessive-compulsive disorder, anxiety, depression and paranoid ideation were side effects more commonly seen in patients using efavirenz for less 
than six months. However, as treatment duration increased (199 to 365 days), even though the scores for patients using efavirenz were higher than PI using 
patients, it was not statistically significant.  
Hoffman CJ13 Dizziness, insomnia, bizarre dreams or hallucinations with efavirenz and was thought to be the responsible agent. The neurocerebellar toxicity affected 22% of 
patients at two weeks. 
Leutscher PDC11 Of the 168 patients who started efavirenz, 90 later discontinued during the follow-up period. Of these 90 patients, 15 discontinued within the first month of 
treatment, 29 between month one and month 12 and the remaining 46 patients after one year. NPSEs are stated as the main reason for efavirenz discontinuation 
but no specific side effects were mentioned. A history of mental illness was reported in the same proportion of patients who continued efavirenz as those who 
discontinued.  
Lochet P16 Abnormal dreams, sleep disorders, memory disorders, restlessness, daytime drowsiness, impaired concentration, sadness, irritability, agitation, emotional 
instability, suicidal ideation, aggressiveness, headaches, feelings of drunkeness, euphoria, hallucinations, anxiety, behavioural troubles, sadness and cognitive 
disorders. At the time of the study, 23 (13.2%) of patients claimed to have frequent or very frequent suicidal ideation. Among these 23 patients, 18 (10.3%) did 
not report having this feeling before initiating efavirenz treatment, four patients did and one did not answer. There were 11 patients who discontinued efavirenz 
due to NPSEs.  
Nelson M14 The most common side effect of the nervous system was dizziness (19% in efavirenz arm and 4% in the etravirine arm). The most common psychiatric disorders 
were sleep disorder (abnormal dreams, insomnia, nightmares, sleep disorders) (9% of patients in the etravirine arm and 32% in the efavirenz arm). There were no 
deaths in the study.  
Rihs TA10 Patients on efavirenz experienced higher levels of depression, anxiety and bad dreams, but not regarding the quality of sleep. There were no differences between 
the groups in terms of cognitive impairment, feelings of derealisation, dizziness or light-headedness.  
Ward DJ17 Mental cloudiness, decreased memory, drunken sensations, difficulty concentrating, agitation, depression, fatigue, sleep difficulty and vivid dreams were 
experienced by patients on efavirenz before the switch to nevirapine was made 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
